FDA Clearance Tracker · P990009-S003
FLOSEAL (R) MATRIX HEMOSTATIC SEALANT AND PROCEED (TM) HEMOSTATIC SEALANT
Last checked: Nov 20, 2026Latest source record: Jul 10, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Jul 10, 2001
Approved
Time to decision
200 days
Received Dec 22, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990009-S003
- Device name
- FLOSEAL (R) MATRIX HEMOSTATIC SEALANT AND PROCEED (TM) HEMOSTATIC SEALANT
- Applicant
- Baxter Healthcare Corp
- Applicant location
- Round Lake, IL
- Received
- Dec 22, 2000
- Decided
- Jul 10, 2001
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P990009
Device type
- Device class
- Class III
- Regulation
- 21 CFR 878.4490
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A DRY FORM OF FLOSEAL(R) MATRIX AND PROCEED(TM) HEMOSTATIC SEALANTS.
Source documents
Other decisions for Baxter Healthcare Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Helion Viewer Suite510(k)
K254265 · Decided May 27, 2026 · 148 days after receipt
Device type: System, Image Processing, Radiological (LLZ) · Radiology & Imaging
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.